{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T08:58:03Z","timestamp":1791622683039,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.msard.2025.106257","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T11:57:37Z","timestamp":1736164657000},"page":"106257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Comparing the efficacy and safety of extended vs standard dosing of ocrelizumab in MS: A systemic review and meta-analysis"],"prefix":"10.1016","volume":"94","author":[{"given":"Mirza Mehmood Ali","family":"Baig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Zulfiqar","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2389-0830","authenticated-orcid":false,"given":"Anusha","family":"Ashkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Naeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrukh","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad Ahmed","family":"Waqas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106257_bib0008","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","article-title":"Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis","volume":"16","author":"Baker","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2025.106257_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103448","article-title":"CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: implications for SARS-CoV-2 vaccinations in multiple sclerosis","volume":"57","author":"Baker","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106257_bib0016","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00415-023-12084-4","article-title":"COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients","volume":"271","author":"Bisecco","year":"2024","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106257_bib0015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585231208311","article-title":"Extended interval dosing of ocrelizumab in patients with multiple sclerosis is not associated with meaningful differences in disease activity","volume":"30","author":"Bou Rjeily","year":"2024","journal-title":"Mult. Scler."},{"issue":"9","key":"10.1016\/j.msard.2025.106257_bib0007","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s40265-017-0757-6","article-title":"Ocrelizumab: first global approval","volume":"77","author":"Frampton","year":"2017","journal-title":"Drugs"},{"issue":"9","key":"10.1016\/j.msard.2025.106257_bib0019","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1111\/ene.15891","article-title":"Ocrelizumab extended-interval dosing in multiple sclerosis during SARS-CoV-2 pandemic: a real-world experience","volume":"30","author":"Guerrieri","year":"2023","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2025.106257_bib0005","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.msard.2025.106257_bib0014","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"1","key":"10.1016\/j.msard.2025.106257_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs."},{"key":"10.1016\/j.msard.2025.106257_bib0006","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"England J. Med"},{"issue":"6","key":"10.1016\/j.msard.2025.106257_bib0001","doi-asserted-by":"crossref","first-page":"s53","DOI":"10.7861\/clinmedicine.16-6-s53","article-title":"Multiple sclerosis, a treatable disease","volume":"16","year":"2016","journal-title":"Clin. Med"},{"issue":"10","key":"10.1016\/j.msard.2025.106257_bib0024","doi-asserted-by":"crossref","first-page":"5353","DOI":"10.3390\/ijms25105353","article-title":"Clinical and immunological impact of ocrelizumab extended interval dosing in multiple sclerosis: a single-center, real-world experience","volume":"25","author":"Nasello","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.msard.2025.106257_bib0021","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1177\/13524585241245296","article-title":"Extended interval dosing with ocrelizumab in multiple sclerosis","volume":"30","author":"Novak","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106257_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105028","article-title":"Ocrelizumab B-cell repopulation-guided extended interval dosing versus standard dosing - similar clinical efficacy with decreased immunoglobulin M deficiency rates","volume":"79","author":"Rempe","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2025.106257_bib0023","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1186\/s12974-023-02900-z","article-title":"Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis","volume":"20","author":"Rodriguez-Mogeda","year":"2023","journal-title":"J. Neuroinflammation."},{"issue":"5","key":"10.1016\/j.msard.2025.106257_bib0012","doi-asserted-by":"crossref","first-page":"e1035","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflammation"},{"issue":"5","key":"10.1016\/j.msard.2025.106257_bib0020","doi-asserted-by":"crossref","first-page":"e1035","DOI":"10.1212\/NXI.0000000000001035","article-title":"Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19","volume":"8","author":"Rolfes","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106257_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103287","article-title":"Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+B-cell repopulation","volume":"56","author":"Sahi","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2025.106257_bib0003","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/ane.13559","article-title":"Standardized mortality ratios in multiple sclerosis: systematic review with meta-analysis","volume":"145","author":"Smyrke","year":"2022","journal-title":"Acta Neurol. Scand."},{"issue":"13","key":"10.1016\/j.msard.2025.106257_bib0013","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1177\/13524585211065711","article-title":"Extended dosing of monoclonal antibodies in multiple sclerosis","volume":"28","author":"van Kempen","year":"2022","journal-title":"Mult. Scler. Houndmills Basingstoke Engl"},{"issue":"7","key":"10.1016\/j.msard.2025.106257_bib0011","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/13524585211028833","article-title":"Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic","volume":"28","author":"van Lierop","year":"2022","journal-title":"Mult. Scler. Houndmills Basingstoke Engl"},{"issue":"14","key":"10.1016\/j.msard.2025.106257_bib0002","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler. J"},{"issue":"10","key":"10.1016\/j.msard.2025.106257_bib0010","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1111\/ene.14690","article-title":"COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response","volume":"28","author":"Zabalza","year":"2021","journal-title":"Eur. J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2025.106257_bib0017","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1007\/s13311-022-01289-6","article-title":"Is it time for ocrelizumab extended interval dosing in relapsing remitting ms? evidence from an italian multicenter experience during the COVID-19 pandemic","volume":"19","author":"Zangh\u00ec","year":"2022","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.msard.2025.106257_bib0018","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2174\/1570159X22666231002142709","article-title":"Ocrelizumab extended interval dosing in primary progressive multiple sclerosis: an italian experience","volume":"22","author":"Zangh\u00ec","year":"2024","journal-title":"Curr. Neuropharmacol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500001X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500001X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T21:03:23Z","timestamp":1739480603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482500001X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":25,"alternative-id":["S221103482500001X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106257","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing the efficacy and safety of extended vs standard dosing of ocrelizumab in MS: A systemic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106257","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106257"}}